Cargando…

Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness

Sleep disorders (somnipathies) are conditions characterized by disruptions of sleep quality or of sleep pattern. They can involve difficulty falling asleep (prolonged sleep onset latency), difficulty staying asleep (disturbance of sleep maintenance), sleep of poor quality (unrefreshing), or combinat...

Descripción completa

Detalles Bibliográficos
Autores principales: Pergolizzi, Joseph V., Taylor, Robert, Raffa, Robert B., Nalamachu, Srinivas, Chopra, Maninder
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932650/
https://www.ncbi.nlm.nih.gov/pubmed/24649369
http://dx.doi.org/10.1155/2014/527109
_version_ 1782304824455331840
author Pergolizzi, Joseph V.
Taylor, Robert
Raffa, Robert B.
Nalamachu, Srinivas
Chopra, Maninder
author_facet Pergolizzi, Joseph V.
Taylor, Robert
Raffa, Robert B.
Nalamachu, Srinivas
Chopra, Maninder
author_sort Pergolizzi, Joseph V.
collection PubMed
description Sleep disorders (somnipathies) are conditions characterized by disruptions of sleep quality or of sleep pattern. They can involve difficulty falling asleep (prolonged sleep onset latency), difficulty staying asleep (disturbance of sleep maintenance), sleep of poor quality (unrefreshing), or combinations of these and can lead to poor health and quality of life problems. A subtype of sleep-maintenance insomnia is middle-of-the-night wakefulness, a relatively common occurrence. Zolpidem, a nonbenzodiazepine benzodiazepine receptor agonist, allosterically modulates an ion channel and increases the influx of Cl(−), thereby dampening the effect of excitatory (sleep disrupting) input. Recently, product label changes to some zolpidem containing products have been implemented by the FDA in order to reduce the risk associated with their morning after residual side effects. A new formulation of zolpidem tartrate (Intermezzo) sublingual tablet, an approved product indicated exclusively for the treatment of middle-of-the-night wakefulness and difficulty returning to sleep, did not have its label changed. We present a short summary of its basic science and clinical attributes in light of the recent regulatory changes for zolpidem products.
format Online
Article
Text
id pubmed-3932650
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-39326502014-03-19 Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness Pergolizzi, Joseph V. Taylor, Robert Raffa, Robert B. Nalamachu, Srinivas Chopra, Maninder Sleep Disord Review Article Sleep disorders (somnipathies) are conditions characterized by disruptions of sleep quality or of sleep pattern. They can involve difficulty falling asleep (prolonged sleep onset latency), difficulty staying asleep (disturbance of sleep maintenance), sleep of poor quality (unrefreshing), or combinations of these and can lead to poor health and quality of life problems. A subtype of sleep-maintenance insomnia is middle-of-the-night wakefulness, a relatively common occurrence. Zolpidem, a nonbenzodiazepine benzodiazepine receptor agonist, allosterically modulates an ion channel and increases the influx of Cl(−), thereby dampening the effect of excitatory (sleep disrupting) input. Recently, product label changes to some zolpidem containing products have been implemented by the FDA in order to reduce the risk associated with their morning after residual side effects. A new formulation of zolpidem tartrate (Intermezzo) sublingual tablet, an approved product indicated exclusively for the treatment of middle-of-the-night wakefulness and difficulty returning to sleep, did not have its label changed. We present a short summary of its basic science and clinical attributes in light of the recent regulatory changes for zolpidem products. Hindawi Publishing Corporation 2014 2014-02-05 /pmc/articles/PMC3932650/ /pubmed/24649369 http://dx.doi.org/10.1155/2014/527109 Text en Copyright © 2014 Joseph V. Pergolizzi Jr. et al. https://creativecommons.org/licenses/by/3.0/ This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Pergolizzi, Joseph V.
Taylor, Robert
Raffa, Robert B.
Nalamachu, Srinivas
Chopra, Maninder
Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness
title Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness
title_full Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness
title_fullStr Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness
title_full_unstemmed Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness
title_short Fast-Acting Sublingual Zolpidem for Middle-of-the-Night Wakefulness
title_sort fast-acting sublingual zolpidem for middle-of-the-night wakefulness
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3932650/
https://www.ncbi.nlm.nih.gov/pubmed/24649369
http://dx.doi.org/10.1155/2014/527109
work_keys_str_mv AT pergolizzijosephv fastactingsublingualzolpidemformiddleofthenightwakefulness
AT taylorrobert fastactingsublingualzolpidemformiddleofthenightwakefulness
AT raffarobertb fastactingsublingualzolpidemformiddleofthenightwakefulness
AT nalamachusrinivas fastactingsublingualzolpidemformiddleofthenightwakefulness
AT chopramaninder fastactingsublingualzolpidemformiddleofthenightwakefulness